-
1
-
-
8144228952
-
Friends or foes-bipolareffects of the tumour stroma in cancer
-
PMID:15516957
-
Mueller MM, Fusenig NE. Friends or foes-bipolareffects of the tumour stroma in cancer. Nat RevCancer 2004; 4:839-49; PMID:15516957; http:// dx.doi.org/10.1038/nrc1477
-
(2004)
Nat RevCancer
, vol.4
, pp. 839-849
-
-
Mueller, M.M.1
Fusenig, N.E.2
-
2
-
-
33846531356
-
The tumour microenvironmentas a target for chemoprevention
-
PMID:17218951
-
Albini A, Sporn MB. The tumour microenvironmentas a target for chemoprevention. Nat Rev Cancer 2007; 7:139-47; PMID:17218951; http://dx.doi. org/10.1038/nrc2067
-
(2007)
Nat Rev Cancer
, vol.7
, pp. 139-147
-
-
Albini, A.1
Sporn, M.B.2
-
3
-
-
84876861350
-
Plasticity of tumourand immune cells: a source of heterogeneity anda cause for therapy resistance?
-
PMID:23535846
-
Hölzel M, Bovier A, Tüting T. Plasticity of tumourand immune cells: a source of heterogeneity anda cause for therapy resistance? Nat Rev Cancer 2013; 13:365-76; PMID:23535846; http://dx.doi. org/10.1038/nrc3498
-
(2013)
Nat Rev Cancer
, vol.13
, pp. 365-376
-
-
Hölzel, M.1
Bovier, A.2
Tüting, T.3
-
4
-
-
79953151458
-
Cancerimmunoediting: integrating immunity's roles incancer suppression and promotion
-
PMID:21436444
-
Schreiber RD, Old LJ, Smyth MJ. Cancerimmunoediting: integrating immunity's roles incancer suppression and promotion. Science 2011; 331:1565-70; PMID:21436444; http://dx.doi. org/10.1126/science.1203486
-
(2011)
Science
, vol.331
, pp. 1565-1570
-
-
Schreiber, R.D.1
Old, L.J.2
Smyth, M.J.3
-
5
-
-
2542430341
-
The three Esof cancer immunoediting
-
PMID:15032581
-
Dunn GP, Old LJ, Schreiber RD. The three Esof cancer immunoediting. Annu Rev Immunol 2004; 22:329-60; PMID:15032581; http://dx.doi. org/10.1146/annurev.immunol.22.012703.104803
-
(2004)
Annu Rev Immunol
, vol.22
, pp. 329-360
-
-
Dunn, G.P.1
Old, L.J.2
Schreiber, R.D.3
-
6
-
-
0036852241
-
Cancer immunoediting: from immunosurveillanceto tumor escape
-
PMID:12407406
-
Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillanceto tumor escape. Nat Immunol 2002; 3:991-8; PMID:12407406; http://dx.doi.org/10.1038/ ni1102-991
-
(2002)
Nat Immunol
, vol.3
, pp. 991-998
-
-
Dunn, G.P.1
Bruce, A.T.2
Ikeda, H.3
Old, L.J.4
Schreiber, R.D.5
-
7
-
-
84884814550
-
Immunosurveillance as a regulator of tissuehomeostasis
-
PMID:23891238
-
Senovilla L, Galluzzi L, Zitvogel L, KroemerG. Immunosurveillance as a regulator of tissuehomeostasis. Trends Immunol 2013; 34:471-81; PMID:23891238; http://dx.doi.org/10.1016/j. it.2013.06.005
-
(2013)
Trends Immunol
, vol.34
, pp. 471-481
-
-
Senovilla, L.1
Galluzzi, L.2
Zitvogel, L.3
Kroemer, G.4
-
8
-
-
84866754237
-
An immunosurveillancemechanism controls cancer cell ploidy
-
PMID:23019653
-
Senovilla L, Vitale I, Martins I, Tailler M, PailleretC, Michaud M, Galluzzi L, Adjemian S, Kepp O, Niso-Santano M, et al. An immunosurveillancemechanism controls cancer cell ploidy. Science 2012; 337:1678-84; PMID:23019653; http://dx.doi. org/10.1126/science.1224922
-
(2012)
Science
, vol.337
, pp. 1678-1684
-
-
Senovilla, L.1
Vitale, I.2
Martins, I.3
Tailler, M.4
Pailleret, C.5
Michaud, M.6
Galluzzi, L.7
Adjemian, S.8
Kepp, O.9
Niso-Santano, M.10
-
9
-
-
84880732251
-
An anticancertherapy-elicited immunosurveillance system thateliminates tetraploid cells
-
PMID:23482968
-
Senovilla L, Vitale I, Martins I, Kepp O, Galluzzi L, Zitvogel L, Castedo M, Kroemer G. An anticancertherapy-elicited immunosurveillance system thateliminates tetraploid cells. Oncoimmunology 2013; 2:e22409; PMID:23482968; http://dx.doi. org/10.4161/onci.22409
-
(2013)
Oncoimmunology
, vol.2
-
-
Senovilla, L.1
Vitale, I.2
Martins, I.3
Kepp, O.4
Galluzzi, L.5
Zitvogel, L.6
Castedo, M.7
Kroemer, G.8
-
10
-
-
84880747672
-
Mechanism of action of conventional and targetedanticancer therapies: reinstating immunosurveillance
-
PMID:23890065
-
Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targetedanticancer therapies: reinstating immunosurveillance. Immunity 2013; 39:74-88; PMID:23890065; http:// dx.doi.org/10.1016/j.immuni.2013.06.014
-
(2013)
Immunity
, vol.39
, pp. 74-88
-
-
Zitvogel, L.1
Galluzzi, L.2
Smyth, M.J.3
Kroemer, G.4
-
11
-
-
84857789296
-
The secret al.y: immunostimulation by anticancerdrugs
-
PMID:22301798
-
Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret al.y: immunostimulation by anticancerdrugs. Nat Rev Drug Discov 2012; 11:215-33; PMID:22301798; http://dx.doi.org/10.1038/ nrd3626
-
(2012)
Nat Rev Drug Discov
, vol.11
, pp. 215-233
-
-
Galluzzi, L.1
Senovilla, L.2
Zitvogel, L.3
Kroemer, G.4
-
13
-
-
84859990399
-
Effective targeting of the tumormicroenvironment for cancer therapy
-
PMID:22493350
-
Jiang P, Li X, Thompson CB, Huang Z, Araiza F, Osgood R, Wei G, Feldmann M, Frost GI, Shepard HM. Effective targeting of the tumormicroenvironment for cancer therapy. Anticancer Res 2012; 32:1203-12; PMID:22493350
-
(2012)
Anticancer Res
, vol.32
, pp. 1203-1212
-
-
Jiang, P.1
Li, X.2
Thompson, C.B.3
Huang, Z.4
Araiza, F.5
Osgood, R.6
Wei, G.7
Feldmann, M.8
Frost, G.I.9
Shepard, H.M.10
-
14
-
-
84872040888
-
Targeting the tumormicroenvironment for cancer therapy
-
PMID:23193058
-
Sounni NE, Noel A. Targeting the tumormicroenvironment for cancer therapy. Clin Chem 2013; 59:85-93; PMID:23193058; http://dx.doi. org/10.1373/clinchem.2012.185363
-
(2013)
Clin Chem
, vol.59
, pp. 85-93
-
-
Sounni, N.E.1
Noel, A.2
-
15
-
-
2442621619
-
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
-
PMID:15136787
-
Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev DrugDiscov 2004; 3:391-400; PMID:15136787; http:// dx.doi.org/10.1038/nrd1381
-
(2004)
Nat Rev DrugDiscov
, vol.3
, pp. 391-400
-
-
Ferrara, N.1
Hillan, K.J.2
Gerber, H.P.3
Novotny, W.4
-
16
-
-
84876872556
-
Dendriticcell inhibition correlates with survival of colorectalcancer patients on bevacizumab treatment
-
PMID:23243624
-
Michielsen AJ, Ryan EJ, O'Sullivan JN. Dendriticcell inhibition correlates with survival of colorectalcancer patients on bevacizumab treatment. Oncoimmunology 2012; 1:1445-7; PMID:23243624; http://dx.doi.org/10.4161/onci.21318
-
(2012)
Oncoimmunology
, vol.1
, pp. 1445-1447
-
-
Michielsen, A.J.1
Ryan, E.J.2
O'Sullivan, J.N.3
-
17
-
-
84883219603
-
Trial watch: Monoclonal antibodies in cancertherapy
-
PMID:23482847
-
Vacchelli E, Eggermont A, Galon J, Sautès-Fridman C, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Monoclonal antibodies in cancertherapy. Oncoimmunology 2013; 2:e22789; PMID:23482847; http://dx.doi.org/10.4161/ onci.22789
-
(2013)
Oncoimmunology
, vol.2
-
-
Vacchelli, E.1
Eggermont, A.2
Galon, J.3
Sautès-Fridman, C.4
Zitvogel, L.5
Kroemer, G.6
Galluzzi, L.7
-
18
-
-
84899115962
-
Trial Watch: Tumortargetingmonoclonal antibodies in cancer therapy
-
Forthcoming
-
Vacchelli E, Aranda F, Eggermont A, Galon J, Sautes-Fridman C, Zitvogel L, et al. Trial Watch: Tumortargetingmonoclonal antibodies in cancer therapy. OncoImmunology 2014; Forthcoming.
-
(2014)
OncoImmunology
-
-
Vacchelli, E.1
Aranda, F.2
Eggermont, A.3
Galon, J.4
Sautes-Fridman, C.5
Zitvogel, L.6
-
19
-
-
77954801079
-
Improved survivalwith ipilimumab in patients with metastaticmelanoma
-
PMID:20525992
-
Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survivalwith ipilimumab in patients with metastaticmelanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/ NEJMoa1003466
-
(2010)
N Engl J Med
, vol.363
, pp. 711-723
-
-
Hodi, F.S.1
O'Day, S.J.2
McDermott, D.F.3
Weber, R.W.4
Sosman, J.A.5
Haanen, J.B.6
Gonzalez, R.7
Robert, C.8
Schadendorf, D.9
Hassel, J.C.10
-
20
-
-
79959772576
-
Ipilimumab plus dacarbazine for previouslyuntreated metastatic melanoma
-
M DJW PMID:21639810
-
Robert C, Thomas L, Bondarenko I, O'Day S, M DJW, Garbe C, Lebbe C, Baurain JF, Testori A, GrobJJ, et al. Ipilimumab plus dacarbazine for previouslyuntreated metastatic melanoma. N Engl J Med 2011; 364:2517-26; PMID:21639810; http://dx.doi. org/10.1056/NEJMoa1104621
-
(2011)
N Engl J Med
, vol.364
, pp. 2517-2526
-
-
Robert, C.1
Thomas, L.2
Bondarenko, I.3
O'Day, S.4
Garbe, C.5
Lebbe, C.6
Baurain, J.F.7
Testori, A.8
Grob, J.J.9
-
21
-
-
75249100054
-
Ipilimumab monotherapyin patients with pretreated advanced melanoma: arandomised, double-blind, multicentre, phase 2, dose-ranging study
-
PMID:20004617
-
Wolchok JD, Neyns B, Linette G, Negrier S, LutzkyJ, Thomas L, Waterfield W, Schadendorf D, SmylieM, Guthrie T Jr., et al. Ipilimumab monotherapyin patients with pretreated advanced melanoma: arandomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11:155-64; PMID:20004617; http://dx.doi.org/10.1016/ S1470-2045(09)70334-1
-
(2010)
Lancet Oncol
, vol.11
, pp. 155-164
-
-
Wolchok, J.D.1
Neyns, B.2
Linette, G.3
Negrier, S.4
Lutzky, J.5
Thomas, L.6
Waterfield, W.7
Schadendorf, D.8
Smylie, M.9
Guthrie Jr., T.10
-
22
-
-
84890285105
-
Inhibiting theinhibitors: Checkpoints blockade in solidtumors
-
PMID:24244910
-
Mavilio D, Lugli E. Inhibiting theinhibitors: Checkpoints blockade in solidtumors. Oncoimmunology 2013; 2:e26535; PMID:24244910; http://dx.doi.org/10.4161/ onci.26535
-
(2013)
Oncoimmunology
, vol.2
-
-
Mavilio, D.1
Lugli, E.2
-
23
-
-
84899112560
-
Trial Watch: Immunostimulatory monoclonal antibodies in cancertherapy
-
Forthcoming
-
Aranda F, Vacchelli E, Eggermont A, Galon J, Fridman WH, Zitvogel L, et al. Trial Watch: Immunostimulatory monoclonal antibodies in cancertherapy. OncoImmunology 2014; Forthcoming.
-
(2014)
OncoImmunology
-
-
Aranda, F.1
Vacchelli, E.2
Eggermont, A.3
Galon, J.4
Fridman, W.H.5
Zitvogel, L.6
-
24
-
-
84885162273
-
Trial Watch: Adoptive cell transfer for anticancerimmunotherapy
-
PMID:23762803
-
Vacchelli E, Eggermont A, Fridman WH, GalonJ, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Adoptive cell transfer for anticancerimmunotherapy. Oncoimmunology 2013; 2:e24238; PMID:23762803; http://dx.doi.org/10.4161/ onci.24238
-
(2013)
Oncoimmunology
, vol.2
-
-
Vacchelli, E.1
Eggermont, A.2
Fridman, W.H.3
Galon, J.4
Tartour, E.5
Zitvogel, L.6
Kroemer, G.7
Galluzzi, L.8
-
25
-
-
84874923977
-
Trial Watch: Immunostimulatory cytokines
-
PMID:22754768
-
Vacchelli E, Galluzzi L, Eggermont A, Galon J, Tartour E, Zitvogel L, Kroemer G. Trial Watch: Immunostimulatory cytokines. Oncoimmunology 2012; 1:493-506; PMID:22754768; http://dx.doi. org/10.4161/onci.20459
-
(2012)
Oncoimmunology
, vol.1
, pp. 493-506
-
-
Vacchelli, E.1
Galluzzi, L.2
Eggermont, A.3
Galon, J.4
Tartour, E.5
Zitvogel, L.6
Kroemer, G.7
-
26
-
-
35448977640
-
The use of FoxP3 as a biomarkerand prognostic factor for malignant human tumors
-
PMID:17932340
-
Schreiber TH. The use of FoxP3 as a biomarkerand prognostic factor for malignant human tumors. Cancer Epidemiol Biomarkers Prev 2007; 16:1931-4; PMID:17932340; http://dx.doi.org/10.1158/1055-9965.EPI-07-0396
-
(2007)
Cancer Epidemiol Biomarkers Prev
, vol.16
, pp. 1931-1934
-
-
Schreiber, T.H.1
-
27
-
-
84875535374
-
Trial watch: Prognostic and predictive value of the immuneinfiltrate in cancer
-
PMID:23243596
-
Senovilla L, Vacchelli E, Galon J, Adjemian S, Eggermont A, Fridman WH, Sautès-Fridman C, Ma Y, Tartour E, Zitvogel L, et al. Trial watch: Prognostic and predictive value of the immuneinfiltrate in cancer. Oncoimmunology 2012; 1:1323-43; PMID:23243596; http://dx.doi.org/10.4161/ onci.22009
-
(2012)
Oncoimmunology
, vol.1
, pp. 1323-1343
-
-
Senovilla, L.1
Vacchelli, E.2
Galon, J.3
Adjemian, S.4
Eggermont, A.5
Fridman, W.H.6
Sautès-Fridman, C.7
Ma, Y.8
Tartour, E.9
Zitvogel, L.10
-
28
-
-
84865782617
-
Optimizing cancer treatments toinduce an acute immune response: radiation Abscopaleffects, PAMPs, and DAMPs
-
PMID:22761465
-
Ludgate CM. Optimizing cancer treatments toinduce an acute immune response: radiation Abscopaleffects, PAMPs, and DAMPs. Clin Cancer Res 2012; 18:4522-5; PMID:22761465; http://dx.doi. org/10.1158/1078-0432.CCR-12-1175
-
(2012)
Clin Cancer Res
, vol.18
, pp. 4522-4525
-
-
Ludgate, C.M.1
-
29
-
-
84873421273
-
Abscopal but desirable: Thecontribution of immune responses to the efficacyof radiotherapy
-
PMID:22754758
-
Kroemer G, Zitvogel L. Abscopal but desirable: Thecontribution of immune responses to the efficacyof radiotherapy. Oncoimmunology 2012; 1:407-8; PMID:22754758; http://dx.doi.org/10.4161/ onci.20074
-
(2012)
Oncoimmunology
, vol.1
, pp. 407-408
-
-
Kroemer, G.1
Zitvogel, L.2
-
30
-
-
84861398744
-
Abscopal effectin a patient with melanoma
-
author reply 2035-6 PMID:22621637
-
Hiniker SM, Chen DS, Knox SJ. Abscopal effectin a patient with melanoma. N Engl J Med 2012; 366:2035-6, author reply 2035-6; PMID:22621637; http://dx.doi.org/10.1056/NEJMc1203984
-
(2012)
N Engl J Med
, vol.366
, pp. 2035-2036
-
-
Hiniker, S.M.1
Chen, D.S.2
Knox, S.J.3
-
31
-
-
84857815877
-
Immunologic correlates of the abscopaleffect in a patient with melanoma
-
PMID:22397654
-
Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Mu Z, Rasalan T, Adamow M, Ritter E, et al. Immunologic correlates of the abscopaleffect in a patient with melanoma. N Engl J Med 2012; 366:925-31; PMID:22397654; http://dx.doi. org/10.1056/NEJMoa1112824
-
(2012)
N Engl J Med
, vol.366
, pp. 925-931
-
-
Postow, M.A.1
Callahan, M.K.2
Barker, C.A.3
Yamada, Y.4
Yuan, J.5
Kitano, S.6
Mu, Z.7
Rasalan, T.8
Adamow, M.9
Ritter, E.10
-
32
-
-
84885754733
-
Trial Watch: Anticancerradioimmunotherapy
-
PMID:24319634
-
Vacchelli E, Vitale I, Tartour E, EggermontA, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Anticancerradioimmunotherapy. Oncoimmunology 2013; 2:e25595; PMID:24319634; http://dx.doi. org/10.4161/onci.25595
-
(2013)
Oncoimmunology
, vol.2
-
-
Vacchelli, E.1
Vitale, I.2
Tartour, E.3
Eggermont, A.4
Sautès-Fridman, C.5
Galon, J.6
Zitvogel, L.7
Kroemer, G.8
Galluzzi, L.9
-
33
-
-
77953613427
-
Chemotherapy and radiotherapy: crypticanticancer vaccines
-
PMID:20403709
-
Ma Y, Kepp O, Ghiringhelli F, Apetoh L, AymericL, Locher C, Tesniere A, Martins I, Ly A, HaynesNM, et al. Chemotherapy and radiotherapy: crypticanticancer vaccines. Semin Immunol 2010; 22:113-24; PMID:20403709; http://dx.doi.org/10.1016/j. smim.2010.03.001
-
(2010)
Semin Immunol
, vol.22
, pp. 113-124
-
-
Ma, Y.1
Kepp, O.2
Ghiringhelli, F.3
Apetoh, L.4
Aymeric, L.5
Locher, C.6
Tesniere, A.7
Martins, I.8
Ly, A.9
Haynes, N.M.10
-
34
-
-
84875944680
-
Chemotherapyand immunomodulation: from immunogenicchemotherapies to novel therapeutic strategies
-
PMID:23560368
-
Ghiringhelli F, Apetoh L. Chemotherapyand immunomodulation: from immunogenicchemotherapies to novel therapeutic strategies. FutureOncol 2013; 9:469-72; PMID:23560368; http:// dx.doi.org/10.2217/fon.12.207
-
(2013)
FutureOncol
, vol.9
, pp. 469-472
-
-
Ghiringhelli, F.1
Apetoh, L.2
-
35
-
-
84857997683
-
A novel pathwaycombining calreticulin exposure and ATP secretionin immunogenic cancer cell death
-
PMID:22252128
-
Garg AD, Krysko DV, Verfaillie T, KaczmarekA, Ferreira GB, Marysael T, Rubio N, Firczuk M, Mathieu C, Roebroek AJ, et al. A novel pathwaycombining calreticulin exposure and ATP secretionin immunogenic cancer cell death. EMBO J 2012; 31:1062-79; PMID:22252128; http://dx.doi. org/10.1038/emboj.2011.497
-
(2012)
EMBO J
, vol.31
, pp. 1062-1079
-
-
Garg, A.D.1
Krysko, D.V.2
Verfaillie, T.3
Kaczmarek, A.4
Ferreira, G.B.5
Marysael, T.6
Rubio, N.7
Firczuk, M.8
Mathieu, C.9
Roebroek, A.J.10
-
36
-
-
84875552922
-
Immunogenic cell death in cancertherapy
-
PMID:23157435
-
Kroemer G, Galluzzi L, Kepp O, ZitvogelL. Immunogenic cell death in cancertherapy. Annu Rev Immunol 2013; 31:51-72; PMID:23157435; http://dx.doi.org/10.1146/ annurev-immunol-032712-100008
-
(2013)
Annu Rev Immunol
, vol.31
, pp. 51-72
-
-
Kroemer, G.1
Galluzzi, L.2
Kepp, O.3
Zitvogel, L.4
-
37
-
-
84870206960
-
Mitochondria: master regulators of danger signalling
-
PMID:23175281
-
Galluzzi L, Kepp O, Kroemer G. Mitochondria: master regulators of danger signalling. Nat Rev MolCell Biol 2012; 13:780-8; PMID:23175281; http:// dx.doi.org/10.1038/nrm3479
-
(2012)
Nat Rev MolCell Biol
, vol.13
, pp. 780-788
-
-
Galluzzi, L.1
Kepp, O.2
Kroemer, G.3
-
38
-
-
84890034987
-
Dangersignalling during cancer cell death: origins, plasticityand regulation
-
PMID:23686135
-
Garg AD, Martin S, Golab J, Agostinis P. Dangersignalling during cancer cell death: origins, plasticityand regulation. Cell Death Differ 2014; 21:26-38; PMID:23686135; http://dx.doi.org/10.1038/ cdd.2013.48
-
(2014)
Cell Death Differ
, vol.21
, pp. 26-38
-
-
Garg, A.D.1
Martin, S.2
Golab, J.3
Agostinis, P.4
-
39
-
-
84881668150
-
Cancerimmunogenicity, danger signals, and DAMPs: what, when, and how?
-
PMID:23900966
-
Garg AD, Dudek AM, Agostinis P. Cancerimmunogenicity, danger signals, and DAMPs: what, when, and how? Biofactors 2013; 39:355-67; PMID:23900966; http://dx.doi.org/10.1002/ biof.1125
-
(2013)
Biofactors
, vol.39
, pp. 355-367
-
-
Garg, A.D.1
Dudek, A.M.2
Agostinis, P.3
-
40
-
-
79952280438
-
Molecular determinantsof immunogenic cell death elicited by anticancerchemotherapy
-
PMID:21249425
-
Kepp O, Galluzzi L, Martins I, Schlemmer F, Adjemian S, Michaud M, Sukkurwala AQ, MengerL, Zitvogel L, Kroemer G. Molecular determinantsof immunogenic cell death elicited by anticancerchemotherapy. Cancer Metastasis Rev 2011; 30:61-9; PMID:21249425; http://dx.doi.org/10.1007/ s10555-011-9273-4
-
(2011)
Cancer Metastasis Rev
, vol.30
, pp. 61-69
-
-
Kepp, O.1
Galluzzi, L.2
Martins, I.3
Schlemmer, F.4
Adjemian, S.5
Michaud, M.6
Sukkurwala, A.Q.7
Menger, L.8
Zitvogel, L.9
Kroemer, G.10
-
41
-
-
84883233976
-
Trial watch: Cardiac glycosides and cancertherapy
-
PMID:23525565
-
Menger L, Vacchelli E, Kepp O, Eggermont A, Tartour E, Zitvogel L, Kroemer G, GalluzziL. Trial watch: Cardiac glycosides and cancertherapy. Oncoimmunology 2013; 2:e23082; PMID:23525565; http://dx.doi.org/10.4161/ onci.23082
-
(2013)
Oncoimmunology
, vol.2
-
-
Menger, L.1
Vacchelli, E.2
Kepp, O.3
Eggermont, A.4
Tartour, E.5
Zitvogel, L.6
Kroemer, G.7
Galluzzi, L.8
-
42
-
-
84864128654
-
Cardiac glycosides exert anticancereffects by inducing immunogenic cell death
-
143ra99, PMID:22814852
-
Menger L, Vacchelli E, Adjemian S, Martins I, Ma Y, Shen S, Yamazaki T, Sukkurwala AQ, Michaud M, Mignot G, et al. Cardiac glycosides exert anticancereffects by inducing immunogenic cell death. SciTransl Med 2012; 4:143ra99; PMID:22814852; http://dx.doi.org/10.1126/scitranslmed.3003807
-
(2012)
SciTransl Med
, vol.4
-
-
Menger, L.1
Vacchelli, E.2
Adjemian, S.3
Martins, I.4
Ma, Y.5
Shen, S.6
Yamazaki, T.7
Sukkurwala, A.Q.8
Michaud, M.9
Mignot, G.10
-
43
-
-
84883785740
-
Inducers of immunogenic cancer celldeath
-
PMID:23391812
-
Dudek AM, Garg AD, Krysko DV, De RuysscherD, Agostinis P. Inducers of immunogenic cancer celldeath. Cytokine Growth Factor Rev 2013; 24:319-33; PMID:23391812; http://dx.doi.org/10.1016/j. cytogfr.2013.01.005
-
(2013)
Cytokine Growth Factor Rev
, vol.24
, pp. 319-333
-
-
Dudek, A.M.1
Garg, A.D.2
Krysko, D.V.3
De Ruysscher, D.4
Agostinis, P.5
-
44
-
-
79551523389
-
Cyclophosphamide synergizeswith type I interferons through systemic dendriticcell reactivation and induction of immunogenictumor apoptosis
-
PMID:21156650
-
Schiavoni G, Sistigu A, Valentini M, Mattei F, SestiliP, Spadaro F, Sanchez M, Lorenzi S, D'Urso MT, Belardelli F, et al. Cyclophosphamide synergizeswith type I interferons through systemic dendriticcell reactivation and induction of immunogenictumor apoptosis. Cancer Res 2011; 71:768-78; PMID:21156650; http://dx.doi.org/10.1158/0008-5472.CAN-10-2788
-
(2011)
Cancer Res
, vol.71
, pp. 768-778
-
-
Schiavoni, G.1
Sistigu, A.2
Valentini, M.3
Mattei, F.4
Sestili, P.5
Spadaro, F.6
Sanchez, M.7
Lorenzi, S.8
D'Urso, M.T.9
Belardelli, F.10
-
45
-
-
29144530630
-
Caspase-dependentimmunogenicity of doxorubicin-induced tumorcell death
-
PMID:16365148
-
Casares N, Pequignot MO, Tesniere A, GhiringhelliF, Roux S, Chaput N, Schmitt E, Hamai A, Hervas-Stubbs S, Obeid M, et al. Caspase-dependentimmunogenicity of doxorubicin-induced tumorcell death. J Exp Med 2005; 202:1691-701; PMID:16365148; http://dx.doi.org/10.1084/ jem.20050915
-
(2005)
J Exp Med
, vol.202
, pp. 1691-1701
-
-
Casares, N.1
Pequignot, M.O.2
Tesniere, A.3
Ghiringhelli, F.4
Roux, S.5
Chaput, N.6
Schmitt, E.7
Hamai, A.8
Hervas-Stubbs, S.9
Obeid, M.10
-
46
-
-
33846057130
-
Calreticulin exposuredictates the immunogenicity of cancer cell death
-
PMID:17187072
-
Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, et al. Calreticulin exposuredictates the immunogenicity of cancer cell death. Nat Med 2007; 13:54-61; PMID:17187072; http:// dx.doi.org/10.1038/nm1523
-
(2007)
Nat Med
, vol.13
, pp. 54-61
-
-
Obeid, M.1
Tesniere, A.2
Ghiringhelli, F.3
Fimia, G.M.4
Apetoh, L.5
Perfettini, J.L.6
Castedo, M.7
Mignot, G.8
Panaretakis, T.9
Casares, N.10
-
47
-
-
79960406242
-
Human tumor cellskilled by anthracyclines induce a tumor-specificimmune response
-
PMID:21602432
-
Fucikova J, Kralikova P, Fialova A, Brtnicky T, Rob L, Bartunkova J, Spísek R. Human tumor cellskilled by anthracyclines induce a tumor-specificimmune response. Cancer Res 2011; 71:4821-33; PMID:21602432; http://dx.doi.org/10.1158/0008-5472.CAN-11-0950
-
(2011)
Cancer Res
, vol.71
, pp. 4821-4833
-
-
Fucikova, J.1
Kralikova, P.2
Fialova, A.3
Brtnicky, T.4
Rob, L.5
Bartunkova, J.6
Spísek, R.7
-
48
-
-
79952533264
-
Restoration of theimmunogenicity of cisplatin-induced cancer celldeath by endoplasmic reticulum stress
-
PMID:21151176
-
Martins I, Kepp O, Schlemmer F, AdjemianS, Tailler M, Shen S, Michaud M, Menger L, Gdoura A, Tajeddine N, et al. Restoration of theimmunogenicity of cisplatin-induced cancer celldeath by endoplasmic reticulum stress. Oncogene 2011; 30:1147-58; PMID:21151176; http://dx.doi. org/10.1038/onc.2010.500
-
(2011)
Oncogene
, vol.30
, pp. 1147-1158
-
-
Martins, I.1
Kepp, O.2
Schlemmer, F.3
Adjemian, S.4
Tailler, M.5
Shen, S.6
Michaud, M.7
Menger, L.8
Gdoura, A.9
Tajeddine, N.10
-
49
-
-
75749147533
-
Immunogenic death of coloncancer cells treated with oxaliplatin
-
PMID:19881547
-
Tesniere A, Schlemmer F, Boige V, Kepp O, MartinsI, Ghiringhelli F, Aymeric L, Michaud M, ApetohL, Barault L, et al. Immunogenic death of coloncancer cells treated with oxaliplatin. Oncogene 2010; 29:482-91; PMID:19881547; http://dx.doi. org/10.1038/onc.2009.356
-
(2010)
Oncogene
, vol.29
, pp. 482-491
-
-
Tesniere, A.1
Schlemmer, F.2
Boige, V.3
Kepp, O.4
Martins, I.5
Ghiringhelli, F.6
Aymeric, L.7
Michaud, M.8
Apetoh, L.9
Barault, L.10
-
50
-
-
84859771379
-
Molecularmechanisms of cisplatin resistance
-
PMID:21892204
-
Galluzzi L, Senovilla L, Vitale I, Michels J, MartinsI, Kepp O, Castedo M, Kroemer G. Molecularmechanisms of cisplatin resistance. Oncogene 2012; 31:1869-83; PMID:21892204; http://dx.doi. org/10.1038/onc.2011.384
-
(2012)
Oncogene
, vol.31
, pp. 1869-1883
-
-
Galluzzi, L.1
Senovilla, L.2
Vitale, I.3
Michels, J.4
Martins, I.5
Kepp, O.6
Castedo, M.7
Kroemer, G.8
-
51
-
-
48549095021
-
Improved cellularpharmacokinetics and pharmacodynamics underliethe wide anticancer activity of sagopilone
-
PMID:18593931
-
Hoffmann J, Vitale I, Buchmann B, Galluzzi L, Schwede W, Senovilla L, Skuballa W, Vivet S, Lichtner RB, Vicencio JM, et al. Improved cellularpharmacokinetics and pharmacodynamics underliethe wide anticancer activity of sagopilone. Cancer Res 2008; 68:5301-8; PMID:18593931; http://dx.doi. org/10.1158/0008-5472.CAN-08-0237
-
(2008)
Cancer Res
, vol.68
, pp. 5301-5308
-
-
Hoffmann, J.1
Vitale, I.2
Buchmann, B.3
Galluzzi, L.4
Schwede, W.5
Senovilla, L.6
Skuballa, W.7
Vivet, S.8
Lichtner, R.B.9
Vicencio, J.M.10
-
52
-
-
84885432340
-
Trial watch: DNA vaccines for cancertherapy
-
PMID:23734328
-
Senovilla L, Vacchelli E, Garcia P, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: DNA vaccines for cancertherapy. Oncoimmunology 2013; 2:e23803; PMID:23734328; http://dx.doi.org/10.4161/ onci.23803
-
(2013)
Oncoimmunology
, vol.2
-
-
Senovilla, L.1
Vacchelli, E.2
Garcia, P.3
Eggermont, A.4
Fridman, W.H.5
Galon, J.6
Zitvogel, L.7
Kroemer, G.8
Galluzzi, L.9
-
53
-
-
84877940678
-
Trial watch: Peptide vaccinesin cancer therapy
-
PMID:23264902
-
Vacchelli E, Martins I, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Peptide vaccinesin cancer therapy. Oncoimmunology 2012; 1:1557-76; PMID:23264902; http://dx.doi.org/10.4161/ onci.22428
-
(2012)
Oncoimmunology
, vol.1
, pp. 1557-1576
-
-
Vacchelli, E.1
Martins, I.2
Eggermont, A.3
Fridman, W.H.4
Galon, J.5
Sautès-Fridman, C.6
Tartour, E.7
Zitvogel, L.8
Kroemer, G.9
Galluzzi, L.10
-
54
-
-
11144242211
-
Timeline: Chemotherapyand the war on cancer
-
PMID:15630416
-
Chabner BA, Roberts TG Jr. Timeline: Chemotherapyand the war on cancer. Nat Rev Cancer 2005; 5:65-72; PMID:15630416; http://dx.doi.org/10.1038/ nrc1529
-
(2005)
Nat Rev Cancer
, vol.5
, pp. 65-72
-
-
Chabner, B.A.1
Roberts Jr., T.G.2
-
55
-
-
84878573270
-
Sequentialchemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed byalemtuzumab consolidation is effective in T-cellprolymphocytic leukemia
-
PMID:23512246
-
Hopfinger G, Busch R, Pflug N, Weit N, Westermann A, Fink AM, Cramer P, Reinart N, Winkler D, Fingerle-Rowson G, et al. Sequentialchemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed byalemtuzumab consolidation is effective in T-cellprolymphocytic leukemia. Cancer 2013; 119:2258-67; PMID:23512246; http://dx.doi.org/10.1002/ cncr.27972
-
(2013)
Cancer
, vol.119
, pp. 2258-2267
-
-
Hopfinger, G.1
Busch, R.2
Pflug, N.3
Weit, N.4
Westermann, A.5
Fink, A.M.6
Cramer, P.7
Reinart, N.8
Winkler, D.9
Fingerle-Rowson, G.10
-
56
-
-
84877814153
-
Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and functionin melanoma patients vaccinated with HLA-classI peptides: impact on the antigen-specific T cellresponse
-
PMID:23589107
-
Camisaschi C, Filipazzi P, Tazzari M, Casati C, Beretta V, Pilla L, Patuzzo R, Maurichi A, Cova A, Maio M, et al. Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and functionin melanoma patients vaccinated with HLA-classI peptides: impact on the antigen-specific T cellresponse. Cancer Immunol Immunother 2013; 62:897-908; PMID:23589107; http://dx.doi. org/10.1007/s00262-013-1397-7
-
(2013)
Cancer Immunol Immunother
, vol.62
, pp. 897-908
-
-
Camisaschi, C.1
Filipazzi, P.2
Tazzari, M.3
Casati, C.4
Beretta, V.5
Pilla, L.6
Patuzzo, R.7
Maurichi, A.8
Cova, A.9
Maio, M.10
-
57
-
-
84891373760
-
Tecemotide (L-BLP25) versus placebo afterchemoradiotherapy for stage III non-small-celllung cancer (START): a randomised, doubleblind, phase 3 trial
-
START trialteam PMID:24331154
-
Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, Nawrocki S, CiuleanuTE, Bosquée L, Trigo JM, et al.; START trialteam. Tecemotide (L-BLP25) versus placebo afterchemoradiotherapy for stage III non-small-celllung cancer (START): a randomised, doubleblind, phase 3 trial. Lancet Oncol 2014; 15:59-68; PMID:24331154; http://dx.doi.org/10.1016/ S1470-2045(13)70510-2
-
(2014)
Lancet Oncol
, vol.15
, pp. 59-68
-
-
Butts, C.1
Socinski, M.A.2
Mitchell, P.L.3
Thatcher, N.4
Havel, L.5
Krzakowski, M.6
Nawrocki, S.7
Ciuleanu, T.E.8
Bosquée, L.9
Trigo, J.M.10
-
58
-
-
84886944930
-
Phase I clinical trial combiningimatinib mesylate and IL-2: HLA-DR(+) NK cell levelscorrelate with disease outcome
-
PMID:23525357
-
Chaput N, Flament C, Locher C, Desbois M, Rey A, Rusakiewicz S, Poirier-Colame V, Pautier P, Le CesneA, Soria JC, et al. Phase I clinical trial combiningimatinib mesylate and IL-2: HLA-DR(+) NK cell levelscorrelate with disease outcome. Oncoimmunology 2013; 2:e23080; PMID:23525357; http://dx.doi. org/10.4161/onci.23080
-
(2013)
Oncoimmunology
, vol.2
-
-
Chaput, N.1
Flament, C.2
Locher, C.3
Desbois, M.4
Rey, A.5
Rusakiewicz, S.6
Poirier-Colame, V.7
Pautier, P.8
Le Cesne, A.9
Soria, J.C.10
-
59
-
-
84886943675
-
Phase I clinical trial combining imatinibmesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinibmesylate
-
PMID:23525192
-
Pautier P, Locher C, Robert C, Deroussent A, FlamentC, Le Cesne A, Rey A, Bahleda R, Ribrag V, Soria JC, et al. Phase I clinical trial combining imatinibmesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinibmesylate. Oncoimmunology 2013; 2:e23079; PMID:23525192; http://dx.doi.org/10.4161/ onci.23079
-
(2013)
Oncoimmunology
, vol.2
-
-
Pautier, P.1
Locher, C.2
Robert, C.3
Deroussent, A.4
Flament, C.5
Le Cesne, A.6
Rey, A.7
Bahleda, R.8
Ribrag, V.9
Soria, J.C.10
-
60
-
-
84871979382
-
Phase I and clinicalpharmacology study of bevacizumab, sorafenib, andlow-dose cyclophosphamide in children and youngadults with refractory/recurrent solid tumors
-
PMID:23143218
-
Navid F, Baker SD, McCarville MB, Stewart CF, Billups CA, Wu J, Davidoff AM, Spunt SL, FurmanWL, McGregor LM, et al. Phase I and clinicalpharmacology study of bevacizumab, sorafenib, andlow-dose cyclophosphamide in children and youngadults with refractory/recurrent solid tumors. ClinCancer Res 2013; 19:236-46; PMID:23143218; http://dx.doi.org/10.1158/1078-0432.CCR-12-1897
-
(2013)
ClinCancer Res
, vol.19
, pp. 236-246
-
-
Navid, F.1
Baker, S.D.2
McCarville, M.B.3
Stewart, C.F.4
Billups, C.A.5
Wu, J.6
Davidoff, A.M.7
Spunt, S.L.8
Furman, W.L.9
McGregor, L.M.10
-
61
-
-
84872135803
-
A phase 1bstudy of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patientswith EpCAM-positive advanced solid tumors
-
PMID:23320927
-
Connor JP, Cristea MC, Lewis NL, Lewis LD, Komarnitsky PB, Mattiacci MR, Felder M, StewartS, Harter J, Henslee-Downey J, et al. A phase 1bstudy of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patientswith EpCAM-positive advanced solid tumors. BMCCancer 2013; 13:20; PMID:23320927; http:// dx.doi.org/10.1186/1471-2407-13-20
-
(2013)
BMCCancer
, vol.13
, pp. 20
-
-
Connor, J.P.1
Cristea, M.C.2
Lewis, N.L.3
Lewis, L.D.4
Komarnitsky, P.B.5
Mattiacci, M.R.6
Felder, M.7
Stewart, S.8
Harter, J.9
Henslee-Downey, J.10
-
62
-
-
84885174214
-
A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advancedcolorectal cancer
-
PMID:24022191
-
Kelley RK, Hwang J, Magbanua MJ, Watt L, BeumerJH, Christner SM, Baruchel S, Wu B, Fong L, YehBM, et al. A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advancedcolorectal cancer. Br J Cancer 2013; 109:1725-34; PMID:24022191; http://dx.doi.org/10.1038/ bjc.2013.553
-
(2013)
Br J Cancer
, vol.109
, pp. 1725-1734
-
-
Kelley, R.K.1
Hwang, J.2
Magbanua, M.J.3
Watt, L.4
Beumer, J.H.5
Christner, S.M.6
Baruchel, S.7
Wu, B.8
Fong, L.9
Yeh, B.M.10
-
63
-
-
84891587587
-
Randomized, multicenter, open-label studyof oxaliplatin plus fluorouracil/leucovorin versusdoxorubicin as palliative chemotherapy in patientswith advanced hepatocellular carcinoma from Asia
-
PMID:23980077
-
Qin S, Bai Y, Lim HY, Thongprasert S, Chao Y, Fan J, Yang TS, Bhudhisawasdi V, Kang WK, ZhouY, et al. Randomized, multicenter, open-label studyof oxaliplatin plus fluorouracil/leucovorin versusdoxorubicin as palliative chemotherapy in patientswith advanced hepatocellular carcinoma from Asia. J Clin Oncol 2013; 31:3501-8; PMID:23980077; http://dx.doi.org/10.1200/JCO.2012.44.5643
-
(2013)
J Clin Oncol
, vol.31
, pp. 3501-3508
-
-
Qin, S.1
Bai, Y.2
Lim, H.Y.3
Thongprasert, S.4
Chao, Y.5
Fan, J.6
Yang, T.S.7
Bhudhisawasdi, V.8
Kang, W.K.9
Zhou, Y.10
-
64
-
-
84873170055
-
Neoadjuvant and adjuvantchemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexatein non-metastatic osteosarcoma of the extremities: aphase II trial in Japan
-
PMID:23433444
-
Kudawara I, Aoki Y, Ueda T, Araki N, Naka N, Nakanishi H, Matsumine A, Ieguchi M, MoriS, Myoui A, et al. Neoadjuvant and adjuvantchemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexatein non-metastatic osteosarcoma of the extremities: aphase II trial in Japan. J Chemother 2013; 25:41-8; PMID:23433444; http://dx.doi.org/10.1179/197394 7812Y.0000000055
-
(2013)
J Chemother
, vol.25
, pp. 41-48
-
-
Kudawara, I.1
Aoki, Y.2
Ueda, T.3
Araki, N.4
Naka, N.5
Nakanishi, H.6
Matsumine, A.7
Ieguchi, M.8
Mori, S.9
Myoui, A.10
-
65
-
-
84878630425
-
A phase IItrial of androgen deprivation therapy (ADT) pluschemotherapy as initial treatment for local failuresor advanced prostate cancer
-
PMID:23604530
-
Amato R, Stepankiw M, Gonzales P. A phase IItrial of androgen deprivation therapy (ADT) pluschemotherapy as initial treatment for local failuresor advanced prostate cancer. Cancer ChemotherPharmacol 2013; 71:1629-34; PMID:23604530; http://dx.doi.org/10.1007/s00280-013-2163-4
-
(2013)
Cancer ChemotherPharmacol
, vol.71
, pp. 1629-1634
-
-
Amato, R.1
Stepankiw, M.2
Gonzales, P.3
-
66
-
-
84872019367
-
Pegylated liposomal doxorubicin as third-linechemotherapy in patients with metastatic transitionalcell carcinoma of urothelial tract: results of a phase IIstudy
-
PMID:23307245
-
Rozzi A, Santini D, Salerno M, Bordin F, Mancuso A, Minniti G, Nardoni C, Corona M, Falbo PT, RecineF, et al. Pegylated liposomal doxorubicin as third-linechemotherapy in patients with metastatic transitionalcell carcinoma of urothelial tract: results of a phase IIstudy. Med Oncol 2013; 30:407; PMID:23307245; http://dx.doi.org/10.1007/s12032-012-0407-5
-
(2013)
Med Oncol
, vol.30
, pp. 407
-
-
Rozzi, A.1
Santini, D.2
Salerno, M.3
Bordin, F.4
Mancuso, A.5
Minniti, G.6
Nardoni, C.7
Corona, M.8
Falbo, P.T.9
Recine, F.10
-
67
-
-
84872981467
-
A phase 2 clinical trial of sequential neoadjuvantchemotherapy with ifosfamide, doxorubicin, andgemcitabine followed by cisplatin, gemcitabine, andifosfamide in locally advanced urothelial cancer: finalresults
-
PMID:22914978
-
Siefker-Radtke AO, Dinney CP, Shen Y, WilliamsDL, Kamat AM, Grossman HB, Millikan RE. A phase 2 clinical trial of sequential neoadjuvantchemotherapy with ifosfamide, doxorubicin, andgemcitabine followed by cisplatin, gemcitabine, andifosfamide in locally advanced urothelial cancer: finalresults. Cancer 2013; 119:540-7; PMID:22914978; http://dx.doi.org/10.1002/cncr.27751
-
(2013)
Cancer
, vol.119
, pp. 540-547
-
-
Siefker-Radtke, A.O.1
Dinney, C.P.2
Shen, Y.3
Williams, D.L.4
Kamat, A.M.5
Grossman, H.B.6
Millikan, R.E.7
-
68
-
-
84878217873
-
A phase I study ofoxaliplatin and doxorubicin in pediatric patients withrelapsed or refractory extracranial non-hematopoieticsolid tumors
-
PMID:23335436
-
Mascarenhas L, Malogolowkin M, Armenian SH, Sposto R, Venkatramani R. A phase I study ofoxaliplatin and doxorubicin in pediatric patients withrelapsed or refractory extracranial non-hematopoieticsolid tumors. Pediatr Blood Cancer 2013; 60:1103-7; PMID:23335436; http://dx.doi.org/10.1002/ pbc.24471
-
(2013)
Pediatr Blood Cancer
, vol.60
, pp. 1103-1107
-
-
Mascarenhas, L.1
Malogolowkin, M.2
Armenian, S.H.3
Sposto, R.4
Venkatramani, R.5
-
69
-
-
84876992498
-
Epirubicin, oxaliplatin, and capecitabine with or without panitumumabfor patients with previously untreated advancedoesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
-
PMID:23594787
-
Waddell T, Chau I, Cunningham D, Gonzalez D, Okines AF, Okines C, Wotherspoon A, Saffery C, Middleton G, Wadsley J, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumabfor patients with previously untreated advancedoesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol 2013; 14:481-9; PMID:23594787; http://dx.doi.org/10.1016/ S1470-2045(13)70096-2
-
(2013)
Lancet Oncol
, vol.14
, pp. 481-489
-
-
Waddell, T.1
Chau, I.2
Cunningham, D.3
Gonzalez, D.4
Okines, A.F.5
Okines, C.6
Wotherspoon, A.7
Saffery, C.8
Middleton, G.9
Wadsley, J.10
-
70
-
-
84896377353
-
A phase I trial of bortezomibin combination with epirubicin, carboplatinand capecitabine (ECarboX) in advancedoesophagogastric adenocarcinoma
-
In press, PMID:23665866
-
Turkington RC, Purcell C, James CR, Millar J, Napier E, Law D, Gallagher R, Morris M, Wilson RH, Eatock MM. A phase I trial of bortezomibin combination with epirubicin, carboplatinand capecitabine (ECarboX) in advancedoesophagogastric adenocarcinoma. Invest New Drugs 2013; In press; PMID:23665866; http://dx.doi. org/10.1007/s10637-013-9970-7.
-
(2013)
Invest New Drugs
-
-
Turkington, R.C.1
Purcell, C.2
James, C.R.3
Millar, J.4
Napier, E.5
Law, D.6
Gallagher, R.7
Morris, M.8
Wilson, R.H.9
Eatock, M.M.10
-
71
-
-
84874108659
-
Methotrexate-paclitaxelepirubicin-carboplatin as second-line chemotherapyin patients with metastatic transitional cellcarcinoma of the bladder pretreated with cisplatingemcitabine: a phase II study
-
PMID:22897883
-
Halim A, Abotouk N. Methotrexate-paclitaxelepirubicin-carboplatin as second-line chemotherapyin patients with metastatic transitional cellcarcinoma of the bladder pretreated with cisplatingemcitabine: a phase II study. Asia Pac J Clin Oncol 2013; 9:60-5; PMID:22897883; http://dx.doi. org/10.1111/j.1743-7563.2012.01554.x
-
(2013)
Asia Pac J Clin Oncol
, vol.9
, pp. 60-65
-
-
Halim, A.1
Abotouk, N.2
-
72
-
-
84884154021
-
Phase I-II clinicaltrial of oxaliplatin, fludarabine, cytarabine, andrituximab therapy in aggressive relapsed/refractorychronic lymphocytic leukemia or Richter syndrome
-
Chronic LymphocyticLeukemia Research Consortium PMID:23810245
-
Tsimberidou AM, Wierda WG, Wen S, PlunkettW, O'Brien S, Kipps TJ, Jones JA, Badoux X, Kantarjian H, Keating MJ; Chronic LymphocyticLeukemia Research Consortium. Phase I-II clinicaltrial of oxaliplatin, fludarabine, cytarabine, andrituximab therapy in aggressive relapsed/refractorychronic lymphocytic leukemia or Richter syndrome. Clin Lymphoma Myeloma Leuk 2013; 13:568-74; PMID:23810245; http://dx.doi.org/10.1016/j. clml.2013.03.012
-
(2013)
Clin Lymphoma Myeloma Leuk
, vol.13
, pp. 568-574
-
-
Tsimberidou, A.M.1
Wierda, W.G.2
Wen, S.3
Plunkett, W.4
O'Brien, S.5
Kipps, T.J.6
Jones, J.A.7
Badoux, X.8
Kantarjian, H.9
Keating, M.J.10
-
73
-
-
84914670329
-
PhaseII clinical trial of oxaliplatin and bevacizumabin refractory germ cell tumors
-
In press, PMID:23388561
-
Jain A, Brames MJ, Vaughn DJ, Einhorn LH. PhaseII clinical trial of oxaliplatin and bevacizumabin refractory germ cell tumors. Am J Clin Oncol 2013; In press; PMID:23388561; http://dx.doi. org/10.1097/COC.0b013e31827de90d.
-
(2013)
Am J Clin Oncol
-
-
Jain, A.1
Brames, M.J.2
Vaughn, D.J.3
Einhorn, L.H.4
-
74
-
-
84875832981
-
Capecitabineand oxaliplatin in combination as first- or secondlinetherapy for metastatic breast cancer: a WisconsinOncology Network trial
-
PMID:23228989
-
Njiaju UO, Tevaarwerk AJ, Kim K, Chang JE, Hansen RM, Champeny TL, Traynor AM, MeadowsS, Van Ummersen L, Powers K, et al. Capecitabineand oxaliplatin in combination as first- or secondlinetherapy for metastatic breast cancer: a WisconsinOncology Network trial. Cancer ChemotherPharmacol 2013; 71:613-8; PMID:23228989; http://dx.doi.org/10.1007/s00280-012-2044-2
-
(2013)
Cancer ChemotherPharmacol
, vol.71
, pp. 613-618
-
-
Njiaju, U.O.1
Tevaarwerk, A.J.2
Kim, K.3
Chang, J.E.4
Hansen, R.M.5
Champeny, T.L.6
Traynor, A.M.7
Meadows, S.8
Van Ummersen, L.9
Powers, K.10
-
75
-
-
84892572211
-
Efficacy and safety of docetaxel combinedwith oxaliplatin as a neoadjuvant chemotherapyregimen for Chinese triple-negative local advancedbreast cancer patients. A prospective, open, andunicentric Phase II clinical trial
-
PMID:22868245
-
Fei F, Chen C, Xue J, Di GH, Lu JS, Liu GY, ShaoZM, Wu J. Efficacy and safety of docetaxel combinedwith oxaliplatin as a neoadjuvant chemotherapyregimen for Chinese triple-negative local advancedbreast cancer patients. A prospective, open, andunicentric Phase II clinical trial. Am J Clin Oncol 2013; 36:545-51; PMID:22868245; http://dx.doi. org/10.1097/COC.0b013e31825d5317
-
(2013)
Am J Clin Oncol
, vol.36
, pp. 545-551
-
-
Fei, F.1
Chen, C.2
Xue, J.3
Di, G.H.4
Lu, J.S.5
Liu, G.Y.6
Shao, Z.M.7
Wu, J.8
-
76
-
-
84887153000
-
A multicenter phaseII study of docetaxel, oxaliplatin, and bevacizumabin first-line therapy for unresectable locally advancedor metastatic non-squamous cell histology nonsmall-cell lung cancer (NSCLC)
-
PMID:24057043
-
Raez LE, Santos ES, Webb RT, Wade J, Brito RA, Karr M, Kennah A, Childs BH. A multicenter phaseII study of docetaxel, oxaliplatin, and bevacizumabin first-line therapy for unresectable locally advancedor metastatic non-squamous cell histology nonsmall-cell lung cancer (NSCLC). Cancer ChemotherPharmacol 2013; 72:1103-10; PMID:24057043; http://dx.doi.org/10.1007/s00280-013-2301-z
-
(2013)
Cancer ChemotherPharmacol
, vol.72
, pp. 1103-1110
-
-
Raez, L.E.1
Santos, E.S.2
Webb, R.T.3
Wade, J.4
Brito, R.A.5
Karr, M.6
Kennah, A.7
Childs, B.H.8
-
77
-
-
84873719135
-
A randomised multicentre phaseII study with cisplatin/docetaxel vs oxaliplatin/ docetaxel as first-line therapy in patients withadvanced or metastatic non-small cell lung cancer
-
PMID:23329236
-
Atmaca A, Al-Batran SE, Werner D, Pauligk C, Güner T, Koepke A, Bernhard H, Wenzel T, BanatAG, Brueck P, et al. A randomised multicentre phaseII study with cisplatin/docetaxel vs oxaliplatin/ docetaxel as first-line therapy in patients withadvanced or metastatic non-small cell lung cancer. Br J Cancer 2013; 108:265-70; PMID:23329236; http://dx.doi.org/10.1038/bjc.2012.555
-
(2013)
Br J Cancer
, vol.108
, pp. 265-270
-
-
Atmaca, A.1
Al-Batran, S.E.2
Werner, D.3
Pauligk, C.4
Güner, T.5
Koepke, A.6
Bernhard, H.7
Wenzel, T.8
Banat, A.G.9
Brueck, P.10
-
78
-
-
84881252044
-
Longtermfollow-up of a phase III study comparingradiotherapy with or without weekly oxaliplatin forlocoregionally advanced nasopharyngeal carcinoma
-
PMID:23661293
-
Wu X, Huang PY, Peng PJ, Lu LX, Han F, Wu SX, Hou X, Zhao HY, Huang Y, Fang WF, et al. Longtermfollow-up of a phase III study comparingradiotherapy with or without weekly oxaliplatin forlocoregionally advanced nasopharyngeal carcinoma. Ann Oncol 2013; 24:2131-6; PMID:23661293; http://dx.doi.org/10.1093/annonc/mdt163
-
(2013)
Ann Oncol
, vol.24
, pp. 2131-2136
-
-
Wu, X.1
Huang, P.Y.2
Peng, P.J.3
Lu, L.X.4
Han, F.5
Wu, S.X.6
Hou, X.7
Zhao, H.Y.8
Huang, Y.9
Fang, W.F.10
-
79
-
-
84884245742
-
A phase II trial of oxaliplatin plus S-1 asa first-line chemotherapy for patients with advancedgastric cancer
-
PMID:24034092
-
Yang L, Song Y, Zhou AP, Qin Q, Chi Y, Huang J, Wang JW. A phase II trial of oxaliplatin plus S-1 asa first-line chemotherapy for patients with advancedgastric cancer. Chin Med J (Engl) 2013; 126:3470-4; PMID:24034092
-
(2013)
Chin Med J (Engl)
, vol.126
, pp. 3470-3474
-
-
Yang, L.1
Song, Y.2
Zhou, A.P.3
Qin, Q.4
Chi, Y.5
Huang, J.6
Wang, J.W.7
-
80
-
-
84875412388
-
A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatmentof metastatic esophagogastric adenocarcinomas
-
PMID:23485624
-
Uronis HE, Bendell JC, Altomare I, Blobe GC, Hsu SD, Morse MA, Pang H, Zafar SY, ConklingP, Favaro J, et al. A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatmentof metastatic esophagogastric adenocarcinomas. Oncologist 2013; 18:271-2; PMID:23485624; http://dx.doi.org/10.1634/theoncologist.2012-0404
-
(2013)
Oncologist
, vol.18
, pp. 271-272
-
-
Uronis, H.E.1
Bendell, J.C.2
Altomare, I.3
Blobe, G.C.4
Hsu, S.D.5
Morse, M.A.6
Pang, H.7
Zafar, S.Y.8
Conkling, P.9
Favaro, J.10
-
81
-
-
84894183457
-
Docetaxel, oxaliplatin and capecitabine (TEX regimen) inpatients with metastatic gastric or gastro-esophagealcancer: Results of a multicenter phase I/II study
-
In press; PMID:24024696
-
Stein A, Arnold D, Thuss-Patience PC, MoehlerM, Grothe W, Seufferlein T, Reinacher-Schick A, Geissler M, Hofheinz RD, Schmoll HJ. Docetaxel, oxaliplatin and capecitabine (TEX regimen) inpatients with metastatic gastric or gastro-esophagealcancer: Results of a multicenter phase I/II study. Acta Oncol 2013; In press; PMID:24024696; http:// dx.doi.org/10.3109/0284186X.2013.833346.
-
(2013)
Acta Oncol
-
-
Stein, A.1
Arnold, D.2
Thuss-Patience, P.C.3
Moehler, M.4
Grothe, W.5
Seufferlein, T.6
Reinacher-Schick, A.7
Geissler, M.8
Hofheinz, R.D.9
Schmoll, H.J.10
-
82
-
-
84887185245
-
Phase I clinicaland pharmacokinetic/pharmacogenetic study ofa triplet regimen of S-1/irinotecan/oxaliplatin inpatients with metastatic colorectal or gastric cancer
-
PMID:23982118
-
Park SR, Hong YS, Lim HS, Seong MW, KongSY, Kim SY, Park YI, Jung KH. Phase I clinicaland pharmacokinetic/pharmacogenetic study ofa triplet regimen of S-1/irinotecan/oxaliplatin inpatients with metastatic colorectal or gastric cancer. Cancer Chemother Pharmacol 2013; 72:953-64; PMID:23982118; http://dx.doi.org/10.1007/ s00280-013-2272-0
-
(2013)
Cancer Chemother Pharmacol
, vol.72
, pp. 953-964
-
-
Park, S.R.1
Hong, Y.S.2
Lim, H.S.3
Seong, M.W.4
Kong, S.Y.5
Kim, S.Y.6
Park, Y.I.7
Jung, K.H.8
-
83
-
-
84885387187
-
Aphase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgeryand adjuvant S-1 chemotherapy in potentiallyresectable gastric or gastroesophageal junctionadenocarcinoma
-
PMID:23921575
-
Park I, Ryu MH, Choi YH, Kang HJ, Yook JH, ParkYS, Kim HJ, Jung HY, Lee GH, Kim KC, et al. Aphase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgeryand adjuvant S-1 chemotherapy in potentiallyresectable gastric or gastroesophageal junctionadenocarcinoma. Cancer Chemother Pharmacol 2013; 72:815-23; PMID:23921575; http://dx.doi. org/10.1007/s00280-013-2257-z
-
(2013)
Cancer Chemother Pharmacol
, vol.72
, pp. 815-823
-
-
Park, I.1
Ryu, M.H.2
Choi, Y.H.3
Kang, H.J.4
Yook, J.H.5
Park, Y.S.6
Kim, H.J.7
Jung, H.Y.8
Lee, G.H.9
Kim, K.C.10
-
84
-
-
84874150344
-
Prospective, open, multicentrephase I/II trial to assess safety and efficacyof neoadjuvant radiochemotherapy with docetaxeland oxaliplatin in patients with adenocarcinomaof the oesophagogastric junction
-
PMID:23394629
-
Moehler M, Gockel I, Roessler HP, Arnold D, Trarbach T, Thomaidis T, Klautke G, Rödel C, Brenner B, Lang H, et al. Prospective, open, multicentrephase I/II trial to assess safety and efficacyof neoadjuvant radiochemotherapy with docetaxeland oxaliplatin in patients with adenocarcinomaof the oesophagogastric junction. BMC Cancer 2013; 13:75; PMID:23394629; http://dx.doi. org/10.1186/1471-2407-13-75
-
(2013)
BMC Cancer
, vol.13
, pp. 75
-
-
Moehler, M.1
Gockel, I.2
Roessler, H.P.3
Arnold, D.4
Trarbach, T.5
Thomaidis, T.6
Klautke, G.7
Rödel, C.8
Brenner, B.9
Lang, H.10
-
85
-
-
84888627652
-
Multicenter phaseII study of oxaliplatin and sorafenib in advancedgastric adenocarcinoma after failure of cisplatinand fluoropyrimidine treatment
-
PMID:24077981
-
Martin-Richard M, Gallego R, Pericay C, GarciaFoncillas J, Queralt B, Casado E, Barriuso J, Iranzo V, Juez I, Visa L, et al. Multicenter phaseII study of oxaliplatin and sorafenib in advancedgastric adenocarcinoma after failure of cisplatinand fluoropyrimidine treatment. A GEMCADstudy. Invest New Drugs 2013; 31:1573-9; PMID:24077981; http://dx.doi.org/10.1007/ s10637-013-0020-2
-
(2013)
A GEMCADstudy. Invest New Drugs
, vol.31
, pp. 1573-1579
-
-
Martin-Richard, M.1
Gallego, R.2
Pericay, C.3
Garcia Foncillas, J.4
Queralt, B.5
Casado, E.6
Barriuso, J.7
Iranzo, V.8
Juez, I.9
Visa, L.10
-
86
-
-
84888588300
-
Phase I study of sunitinib plus capecitabine/ cisplatin or capecitabine/oxaliplatin in advancedgastric cancer
-
PMID:24091982
-
Lee KW, Park SR, Oh DY, Park YI, KhosravanR, Lin X, Lee SY, Roh EJ, Valota O, Lechuga MJ, et al. Phase I study of sunitinib plus capecitabine/ cisplatin or capecitabine/oxaliplatin in advancedgastric cancer. Invest New Drugs 2013; 31:1547-58; PMID:24091982; http://dx.doi.org/10.1007/ s10637-013-0032-y
-
(2013)
Invest New Drugs
, vol.31
, pp. 1547-1558
-
-
Lee, K.W.1
Park, S.R.2
Oh, D.Y.3
Park, Y.I.4
Khosravan, R.5
Lin, X.6
Lee, S.Y.7
Roh, E.J.8
Valota, O.9
Lechuga, M.J.10
-
87
-
-
84892786410
-
Arandomized phase II study of weekly docetaxel/ cisplatin versus weekly docetaxel/oxaliplatin asfirst-line therapy for patients with advanced gastriccancer
-
PMID:24202666
-
Kim YS, Sym SJ, Park SH, Park I, Hong J, AhnHK, Park J, Cho EK, Lee WK, Chung M, et al. Arandomized phase II study of weekly docetaxel/ cisplatin versus weekly docetaxel/oxaliplatin asfirst-line therapy for patients with advanced gastriccancer. Cancer Chemother Pharmacol 2014; 73:163-9; PMID:24202666; http://dx.doi.org/10.1007/ s00280-013-2334-3
-
(2014)
Cancer Chemother Pharmacol
, vol.73
, pp. 163-169
-
-
Kim, Y.S.1
Sym, S.J.2
Park, S.H.3
Park, I.4
Hong, J.5
Ahn, H.K.6
Park, J.7
Cho, E.K.8
Lee, W.K.9
Chung, M.10
-
88
-
-
84879418486
-
Phase I trial of docetaxel, oxaliplatin, and capecitabine (DOC) in untreated gastriccancer patients
-
PMID:22669361
-
Frustaci S, Buonadonna A, Turchet E, Corona G, Tabaro G, Miolo G, Torrisi E, Lo Re G, TumoloS, Toffoli G. Phase I trial of docetaxel, oxaliplatin, and capecitabine (DOC) in untreated gastriccancer patients. Int J Clin Oncol 2013; 18:510-6; PMID:22669361; http://dx.doi.org/10.1007/ s10147-012-0410-z
-
(2013)
Int J Clin Oncol
, vol.18
, pp. 510-516
-
-
Frustaci, S.1
Buonadonna, A.2
Turchet, E.3
Corona, G.4
Tabaro, G.5
Miolo, G.6
Torrisi, E.7
Lo Re, G.8
Tumolo, S.9
Toffoli, G.10
-
89
-
-
84911425630
-
Docetaxel, oxaliplatin, andcapecitabine combination chemotherapy formetastatic gastric cancer
-
Inpress, PMID:24318671
-
Di Lauro L, Vici P, Belli F, Tomao S, Fattoruso SI, Arena MG, Pizzuti L, Giannarelli D, Paoletti G, Barba M, et al. Docetaxel, oxaliplatin, andcapecitabine combination chemotherapy formetastatic gastric cancer. Gastric Cancer 2013; Inpress; PMID:24318671; http://dx.doi.org/10.1007/ s10120-013-0321-3.
-
(2013)
Gastric Cancer
-
-
Di Lauro, L.1
Vici, P.2
Belli, F.3
Tomao, S.4
Fattoruso, S.I.5
Arena, M.G.6
Pizzuti, L.7
Giannarelli, D.8
Paoletti, G.9
Barba, M.10
-
90
-
-
84884819988
-
A Phase Istudy of the combination of oxaliplatin/docetaxeland vandetanib for the treatment of advancedgastroesophageal cancer
-
PMID:23553066
-
Halmos B, Jia Y, Bokar JA, Fu P, Adelstein DJ, Juergens R, Rodal MB, Dowlati A. A Phase Istudy of the combination of oxaliplatin/docetaxeland vandetanib for the treatment of advancedgastroesophageal cancer. Invest New Drugs 2013; 31:1244-50; PMID:23553066; http://dx.doi. org/10.1007/s10637-013-9945-8
-
(2013)
Invest New Drugs
, vol.31
, pp. 1244-1250
-
-
Halmos, B.1
Jia, Y.2
Bokar, J.A.3
Fu, P.4
Adelstein, D.J.5
Juergens, R.6
Rodal, M.B.7
Dowlati, A.8
-
91
-
-
84878876390
-
A two-cohort phase I study of weeklyoxaliplatin and gemcitabine, then oxaliplatin, gemcitabine, and erlotinib during radiotherapy forunresectable pancreatic carcinoma
-
PMID:22547007
-
Raftery L, Tepper JE, Goldberg RM, BlackstockAW, Aklilu M, Bernard SA, Ivanova A, Davies JM, O'Neil BH. A two-cohort phase I study of weeklyoxaliplatin and gemcitabine, then oxaliplatin, gemcitabine, and erlotinib during radiotherapy forunresectable pancreatic carcinoma. Am J Clin Oncol 2013; 36:250-3; PMID:22547007; http://dx.doi. org/10.1097/COC.0b013e3182467f22
-
(2013)
Am J Clin Oncol
, vol.36
, pp. 250-253
-
-
Raftery, L.1
Tepper, J.E.2
Goldberg, R.M.3
Blackstock, A.W.4
Aklilu, M.5
Bernard, S.A.6
Ivanova, A.7
Davies, J.M.8
O'Neil, B.H.9
-
92
-
-
84880921318
-
A phase Istudy of sorafenib, oxaliplatin and 2 days of high dosecapecitabine in advanced pancreatic and biliary tractcancer: a Wisconsin oncology network study
-
PMID:23263993
-
LoConte NK, Holen KD, Schelman WR, MulkerinDL, Deming DA, Hernan HR, Traynor AM, Goggins T, Groteluschen D, Oettel K, et al. A phase Istudy of sorafenib, oxaliplatin and 2 days of high dosecapecitabine in advanced pancreatic and biliary tractcancer: a Wisconsin oncology network study. InvestNew Drugs 2013; 31:943-8; PMID:23263993; http://dx.doi.org/10.1007/s10637-012-9916-5
-
(2013)
InvestNew Drugs
, vol.31
, pp. 943-948
-
-
LoConte, N.K.1
Holen, K.D.2
Schelman, W.R.3
Mulkerin, D.L.4
Deming, D.A.5
Hernan, H.R.6
Traynor, A.M.7
Goggins, T.8
Groteluschen, D.9
Oettel, K.10
-
93
-
-
84880573171
-
Amulti-institutional phase 2 study of neoadjuvantgemcitabine and oxaliplatin with radiation therapyin patients with pancreatic cancer
-
PMID:23720019
-
Kim EJ, Ben-Josef E, Herman JM, Bekaii-Saab T, Dawson LA, Griffith KA, Francis IR, Greenson JK, Simeone DM, Lawrence TS, et al. Amulti-institutional phase 2 study of neoadjuvantgemcitabine and oxaliplatin with radiation therapyin patients with pancreatic cancer. Cancer 2013; 119:2692-700; PMID:23720019; http://dx.doi. org/10.1002/cncr.28117
-
(2013)
Cancer
, vol.119
, pp. 2692-2700
-
-
Kim, E.J.1
Ben-Josef, E.2
Herman, J.M.3
Bekaii-Saab, T.4
Dawson, L.A.5
Griffith, K.A.6
Francis, I.R.7
Greenson, J.K.8
Simeone, D.M.9
Lawrence, T.S.10
-
94
-
-
84884744581
-
AMulticenter Phase II Trial of Gemcitabine PlusOxaliplatin in Unresectable Gallbladder Cancer
-
PMID:24073318
-
Woo SM, Lee SH, Yoo JW, Yang KY, Seo JG, ParkJK, Hwang JH, Lee WJ, Ryu JK, Kim YT, et al. AMulticenter Phase II Trial of Gemcitabine PlusOxaliplatin in Unresectable Gallbladder Cancer. Gut Liver 2013; 7:594-8; PMID:24073318; http:// dx.doi.org/10.5009/gnl.2013.7.5.594
-
(2013)
Gut Liver
, vol.7
, pp. 594-598
-
-
Woo, S.M.1
Lee, S.H.2
Yoo, J.W.3
Yang, K.Y.4
Seo, J.G.5
Park, J.K.6
Hwang, J.H.7
Lee, W.J.8
Ryu, J.K.9
Kim, Y.T.10
-
95
-
-
84881133586
-
Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreatedepithelial ovarian cancer patients
-
PMID:23927758
-
Vici P, Sergi D, Pizzuti L, Mariani L, Arena MG, Barba M, Maugeri-Saccà M, Vincenzoni C, VizzaE, Corrado G, et al. Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreatedepithelial ovarian cancer patients. J Exp Clin CancerRes 2013; 32:49; PMID:23927758; http://dx.doi. org/10.1186/1756-9966-32-49
-
(2013)
J Exp Clin CancerRes
, vol.32
, pp. 49
-
-
Vici, P.1
Sergi, D.2
Pizzuti, L.3
Mariani, L.4
Arena, M.G.5
Barba, M.6
Maugeri-Saccà, M.7
Vincenzoni, C.8
Vizza, E.9
Corrado, G.10
-
96
-
-
84888309055
-
A phase 2 study of oxaliplatin combined withcontinuous infusion topotecan for patients withpreviously treated ovarian cancer
-
PMID:24172094
-
Stein SM, Tiersten A, Hochster HS, Blank SV, PothuriB, Curtin J, Shapira I, Levinson B, Ivy P, Joseph B, et al. A phase 2 study of oxaliplatin combined withcontinuous infusion topotecan for patients withpreviously treated ovarian cancer. Int J GynecolCancer 2013; 23:1577-82; PMID:24172094; http:// dx.doi.org/10.1097/IGC.0b013e3182a809e0
-
(2013)
Int J GynecolCancer
, vol.23
, pp. 1577-1582
-
-
Stein, S.M.1
Tiersten, A.2
Hochster, H.S.3
Blank, S.V.4
Pothuri, B.5
Curtin, J.6
Shapira, I.7
Levinson, B.8
Ivy, P.9
Joseph, B.10
-
97
-
-
84879796431
-
A phase II study ofgemcitabine and oxaliplatin in advanced transitionalcell carcinoma of the bladder
-
PMID:23636451
-
Eroglu Z, Fruehauf JP. A phase II study ofgemcitabine and oxaliplatin in advanced transitionalcell carcinoma of the bladder. Cancer ChemotherPharmacol 2013; 72:263-7; PMID:23636451; http:// dx.doi.org/10.1007/s00280-013-2178-x
-
(2013)
Cancer ChemotherPharmacol
, vol.72
, pp. 263-267
-
-
Eroglu, Z.1
Fruehauf, J.P.2
-
98
-
-
84879795373
-
A phase I trial ofoxaliplatin in combination with docetaxel in patientswith advanced solid tumors
-
PMID:23712328
-
Iqbal S, Lenz HJ, Gandara DR, Shibata SI, GroshenS, Synold TW, Newman EM. A phase I trial ofoxaliplatin in combination with docetaxel in patientswith advanced solid tumors. Cancer ChemotherPharmacol 2013; 72:85-91; PMID:23712328; http://dx.doi.org/10.1007/s00280-013-2171-4
-
(2013)
Cancer ChemotherPharmacol
, vol.72
, pp. 85-91
-
-
Iqbal, S.1
Lenz, H.J.2
Gandara, D.R.3
Shibata, S.I.4
Groshen, S.5
Synold, T.W.6
Newman, E.M.7
-
99
-
-
84880916267
-
A phase II study to evaluate the efficacy and toxicityof oxaliplatin in combination with gemcitabine incarcinoma of unknown primary
-
PMID:22218909
-
Carlson H, Lenzi R, Raber MN, Varadhachary GR. A phase II study to evaluate the efficacy and toxicityof oxaliplatin in combination with gemcitabine incarcinoma of unknown primary. Int J Clin Oncol 2013; 18:226-31; PMID:22218909; http://dx.doi. org/10.1007/s10147-011-0366-4
-
(2013)
Int J Clin Oncol
, vol.18
, pp. 226-231
-
-
Carlson, H.1
Lenzi, R.2
Raber, M.N.3
Varadhachary, G.R.4
-
100
-
-
84885615786
-
Autophagy-dependent ATP release fromdying cells via lysosomal exocytosis
-
PMID:23989612
-
Wang Y, Martins I, Ma Y, Kepp O, Galluzzi L, Kroemer G. Autophagy-dependent ATP release fromdying cells via lysosomal exocytosis. Autophagy 2013; 9:1624-5; PMID:23989612; http://dx.doi. org/10.4161/auto.25873
-
(2013)
Autophagy
, vol.9
, pp. 1624-1625
-
-
Wang, Y.1
Martins, I.2
Ma, Y.3
Kepp, O.4
Galluzzi, L.5
Kroemer, G.6
-
101
-
-
84890103572
-
Molecular mechanisms of ATPsecretion during immunogenic cell death
-
PMID:23852373
-
Martins I, Wang Y, Michaud M, Ma Y, SukkurwalaAQ, Shen S, Kepp O, Métivier D, Galluzzi L, Perfettini JL, et al. Molecular mechanisms of ATPsecretion during immunogenic cell death. Cell DeathDiffer 2014; 21:79-91; PMID:23852373; http:// dx.doi.org/10.1038/cdd.2013.75
-
(2014)
Cell DeathDiffer
, vol.21
, pp. 79-91
-
-
Martins, I.1
Wang, Y.2
Michaud, M.3
Ma, Y.4
Sukkurwala, A.Q.5
Shen, S.6
Kepp, O.7
Métivier, D.8
Galluzzi, L.9
Perfettini, J.L.10
-
102
-
-
84892942936
-
CCL2/CCR2-Dependent Recruitmentof Functional Antigen-Presenting Cells into Tumorsupon Chemotherapy
-
PMID:24302580
-
Ma Y, Mattarollo SR, Adjemian S, Yang H, AymericL, Hannani D, Portela Catani JP, Duret H, Teng MW, Kepp O, et al. CCL2/CCR2-Dependent Recruitmentof Functional Antigen-Presenting Cells into Tumorsupon Chemotherapy. Cancer Res 2014; 74:436-45; PMID:24302580; http://dx.doi.org/10.1158/0008-5472.CAN-13-1265.
-
(2014)
Cancer Res
, vol.74
, pp. 436-445
-
-
Ma, Y.1
Mattarollo, S.R.2
Adjemian, S.3
Yang, H.4
Aymeric, L.5
Hannani, D.6
Portela Catani, J.P.7
Duret, H.8
Teng, M.W.9
Kepp, O.10
-
103
-
-
84886943382
-
ATP-dependent recruitment, survival and differentiation of dendritic cellprecursors in the tumor bed after anticancerchemotherapy
-
PMID:23894718
-
Ma Y, Adjemian S, Yang H, Catani JP, HannaniD, Martins I, Michaud M, Kepp O, SukkurwalaAQ, Vacchelli E, et al. ATP-dependent recruitment, survival and differentiation of dendritic cellprecursors in the tumor bed after anticancerchemotherapy. Oncoimmunology 2013; 2:e24568; PMID:23894718; http://dx.doi.org/10.4161/ onci.24568
-
(2013)
Oncoimmunology
, vol.2
-
-
Ma, Y.1
Adjemian, S.2
Yang, H.3
Catani, J.P.4
Hannani, D.5
Martins, I.6
Michaud, M.7
Kepp, O.8
Sukkurwala, A.Q.9
Vacchelli, E.10
-
104
-
-
84876753532
-
Anticancer chemotherapyinducedintratumoral recruitment and differentiationof antigen-presenting cells
-
PMID:23562161
-
Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H, Portela Catani JP, Hannani D, Duret H, Steegh K, et al. Anticancer chemotherapyinducedintratumoral recruitment and differentiationof antigen-presenting cells. Immunity 2013; 38:729-41; PMID:23562161; http://dx.doi.org/10.1016/j. immuni.2013.03.003
-
(2013)
Immunity
, vol.38
, pp. 729-741
-
-
Ma, Y.1
Adjemian, S.2
Mattarollo, S.R.3
Yamazaki, T.4
Aymeric, L.5
Yang, H.6
Portela Catani, J.P.7
Hannani, D.8
Duret, H.9
Steegh, K.10
-
105
-
-
84886944722
-
Tumor necrosisfactor is dispensable for the success of immunogenicanticancer chemotherapy
-
PMID:23894723
-
Ma Y, Yamazaki T, Yang H, Kepp O, Galluzzi L, Zitvogel L, Smyth MJ, Kroemer G. Tumor necrosisfactor is dispensable for the success of immunogenicanticancer chemotherapy. Oncoimmunology 2013; 2:e24786; PMID:23894723; http://dx.doi. org/10.4161/onci.24786
-
(2013)
Oncoimmunology
, vol.2
-
-
Ma, Y.1
Yamazaki, T.2
Yang, H.3
Kepp, O.4
Galluzzi, L.5
Zitvogel, L.6
Smyth, M.J.7
Kroemer, G.8
-
106
-
-
84888059687
-
The intestinal microbiota modulatesthe anticancer immune effects of cyclophosphamide
-
PMID:24264990
-
Viaud S, Saccheri F, Mignot G, Yamazaki T, DaillèreR, Hannani D, Enot DP, Pfirschke C, Engblom C, Pittet MJ, et al. The intestinal microbiota modulatesthe anticancer immune effects of cyclophosphamide. Science 2013; 342:971-6; PMID:24264990; http:// dx.doi.org/10.1126/science.1240537
-
(2013)
Science
, vol.342
, pp. 971-976
-
-
Viaud, S.1
Saccheri, F.2
Mignot, G.3
Yamazaki, T.4
Daillère, R.5
Hannani, D.6
Enot, D.P.7
Pfirschke, C.8
Engblom, C.9
Pittet, M.J.10
-
107
-
-
84888049920
-
Commensal bacteria controlcancer response to therapy by modulating thetumor microenvironment
-
PMID:24264989
-
Iida N, Dzutsev A, Stewart CA, Smith L, BouladouxN, Weingarten RA, Molina DA, Salcedo R, BackT, Cramer S, et al. Commensal bacteria controlcancer response to therapy by modulating thetumor microenvironment. Science 2013; 342:967-70; PMID:24264989; http://dx.doi.org/10.1126/ science.1240527
-
(2013)
Science
, vol.342
, pp. 967-970
-
-
Iida, N.1
Dzutsev, A.2
Stewart, C.A.3
Smith, L.4
Bouladoux, N.5
Weingarten, R.A.6
Molina, D.A.7
Salcedo, R.8
Back, T.9
Cramer, S.10
-
108
-
-
84879783969
-
ROS-induced autophagy in cancer cells assists inevasion from determinants of immunogenic cell death
-
PMID:23800749
-
Garg AD, Dudek AM, Ferreira GB, Verfaillie T, Vandenabeele P, Krysko DV, Mathieu C, AgostinisP. ROS-induced autophagy in cancer cells assists inevasion from determinants of immunogenic cell death. Autophagy 2013; 9:1292-307; PMID:23800749; http://dx.doi.org/10.4161/auto.25399
-
(2013)
Autophagy
, vol.9
, pp. 1292-1307
-
-
Garg, A.D.1
Dudek, A.M.2
Ferreira, G.B.3
Verfaillie, T.4
Vandenabeele, P.5
Krysko, D.V.6
Mathieu, C.7
Agostinis, P.8
-
109
-
-
84882825448
-
Pro-apoptotic signaling induced by photooxidativeER stress is amplified by Noxa, not Bim
-
PMID:23916707
-
Verfaillie T, van Vliet A, Garg AD, Dewaele M, Rubio N, Gupta S, de Witte P, Samali A, AgostinisP. Pro-apoptotic signaling induced by photooxidativeER stress is amplified by Noxa, not Bim. Biochem Biophys Res Commun 2013; 438:500-6; PMID:23916707; http://dx.doi.org/10.1016/j. bbrc.2013.07.107
-
(2013)
Biochem Biophys Res Commun
, vol.438
, pp. 500-506
-
-
Verfaillie, T.1
van Vliet, A.2
Garg, A.D.3
Dewaele, M.4
Rubio, N.5
Gupta, S.6
de Witte, P.7
Samali, A.8
Agostinis, P.9
-
110
-
-
84858000639
-
Enlightening theimpact of immunogenic cell death in photodynamiccancer therapy
-
PMID:22252132
-
Galluzzi L, Kepp O, Kroemer G. Enlightening theimpact of immunogenic cell death in photodynamiccancer therapy. EMBO J 2012; 31:1055-7; PMID:22252132; http://dx.doi.org/10.1038/ emboj.2012.2
-
(2012)
EMBO J
, vol.31
, pp. 1055-1057
-
-
Galluzzi, L.1
Kepp, O.2
Kroemer, G.3
-
111
-
-
84884909735
-
Circulating nucleosomesand immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advancedpancreatic cancer undergoing chemotherapy
-
PMID:23729200
-
Wittwer C, Boeck S, Heinemann V, Haas M, StieberP, Nagel D, Holdenrieder S. Circulating nucleosomesand immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advancedpancreatic cancer undergoing chemotherapy. Int JCancer 2013; 133:2619-30; PMID:23729200
-
(2013)
Int JCancer
, vol.133
, pp. 2619-2630
-
-
Wittwer, C.1
Boeck, S.2
Heinemann, V.3
Haas, M.4
Stieber, P.5
Nagel, D.6
Holdenrieder, S.7
-
112
-
-
84872798053
-
Circulatingimmunogenic cell death biomarkers HMGB1 andRAGE in breast cancer patients during neoadjuvantchemotherapy
-
PMID:22983919
-
Stoetzer OJ, Fersching DM, Salat C, SteinkohlO, Gabka CJ, Hamann U, Braun M, FellerAM, Heinemann V, Siegele B, et al. Circulatingimmunogenic cell death biomarkers HMGB1 andRAGE in breast cancer patients during neoadjuvantchemotherapy. Tumour Biol 2013; 34:81-90; PMID:22983919; http://dx.doi.org/10.1007/ s13277-012-0513-1
-
(2013)
Tumour Biol
, vol.34
, pp. 81-90
-
-
Stoetzer, O.J.1
Fersching, D.M.2
Salat, C.3
Steinkohl, O.4
Gabka, C.J.5
Hamann, U.6
Braun, M.7
Feller, A.M.8
Heinemann, V.9
Siegele, B.10
-
113
-
-
84874943967
-
Immunogeniccell death biomarkers HMGB1, RAGE, and DNAseindicate response to radioembolization therapy andprognosis in colorectal cancer patients
-
PMID:23047645
-
Fahmueller YN, Nagel D, Hoffmann RT, Tatsch K, Jakobs T, Stieber P, Holdenrieder S. Immunogeniccell death biomarkers HMGB1, RAGE, and DNAseindicate response to radioembolization therapy andprognosis in colorectal cancer patients. Int J Cancer 2013; 132:2349-58; PMID:23047645; http://dx.doi. org/10.1002/ijc.27894
-
(2013)
Int J Cancer
, vol.132
, pp. 2349-2358
-
-
Fahmueller, Y.N.1
Nagel, D.2
Hoffmann, R.T.3
Tatsch, K.4
Jakobs, T.5
Stieber, P.6
Holdenrieder, S.7
-
114
-
-
84886944380
-
Trial Watch: Adoptive cell transferimmunotherapy
-
PMID:22737606
-
Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial Watch: Adoptive cell transferimmunotherapy. Oncoimmunology 2012; 1:306-15; PMID:22737606; http://dx.doi.org/10.4161/ onci.19549
-
(2012)
Oncoimmunology
, vol.1
, pp. 306-315
-
-
Galluzzi, L.1
Vacchelli, E.2
Eggermont, A.3
Fridman, W.H.4
Galon, J.5
Sautès-Fridman, C.6
Tartour, E.7
Zitvogel, L.8
Kroemer, G.9
-
115
-
-
84890277186
-
Continuous 4-1BB co-stimulatory signals for theoptimal expansion of tumor-infiltrating lymphocytesfor adoptive T-cell therapy
-
PMID:24319633
-
Chacon JA, Pilon-Thomas S, Sarnaik AA, RadvanyiLG. Continuous 4-1BB co-stimulatory signals for theoptimal expansion of tumor-infiltrating lymphocytesfor adoptive T-cell therapy. Oncoimmunology 2013; 2:e25581; PMID:24319633; http://dx.doi. org/10.4161/onci.25581
-
(2013)
Oncoimmunology
, vol.2
-
-
Chacon, J.A.1
Pilon-Thomas, S.2
Sarnaik, A.A.3
Radvanyi, L.G.4
-
116
-
-
81255138298
-
Tumor-derivedautophagosome vaccine: mechanism of crosspresentationand therapeutic efficacy
-
PMID:22068657
-
Li Y, Wang LX, Pang P, Cui Z, Aung S, HaleyD, Fox BA, Urba WJ, Hu HM. Tumor-derivedautophagosome vaccine: mechanism of crosspresentationand therapeutic efficacy. Clin CancerRes 2011; 17:7047-57; PMID:22068657; http:// dx.doi.org/10.1158/1078-0432.CCR-11-0951
-
(2011)
Clin CancerRes
, vol.17
, pp. 7047-7057
-
-
Li, Y.1
Wang, L.X.2
Pang, P.3
Cui, Z.4
Aung, S.5
Haley, D.6
Fox, B.A.7
Urba, W.J.8
Hu, H.M.9
-
117
-
-
84867517513
-
Sorafenib has potent antitumoractivity against multiple myeloma in vitro, ex vivo, and in vivo in the 5T33MM mouse model
-
PMID:22952216
-
Kharaziha P, De Raeve H, Fristedt C, Li Q, GruberA, Johnsson P, Kokaraki G, Panzar M, Laane E, Osterborg A, et al. Sorafenib has potent antitumoractivity against multiple myeloma in vitro, ex vivo, and in vivo in the 5T33MM mouse model. CancerRes 2012; 72:5348-62; PMID:22952216; http:// dx.doi.org/10.1158/0008-5472.CAN-12-0658
-
(2012)
CancerRes
, vol.72
, pp. 5348-5362
-
-
Kharaziha, P.1
De Raeve, H.2
Fristedt, C.3
Li, Q.4
Gruber, A.5
Johnsson, P.6
Kokaraki, G.7
Panzar, M.8
Laane, E.9
Osterborg, A.10
-
118
-
-
84863169200
-
Targeting of distinctsignaling cascades and cancer-associated fibroblastsdefine the efficacy of Sorafenib against prostatecancer cells
-
PMID:22278289
-
Kharaziha P, Rodriguez P, Li Q, Rundqvist H, Björklund AC, Augsten M, Ullén A, Egevad L, Wiklund P, Nilsson S, et al. Targeting of distinctsignaling cascades and cancer-associated fibroblastsdefine the efficacy of Sorafenib against prostatecancer cells. Cell Death Dis 2012; 3:e262; PMID:22278289; http://dx.doi.org/10.1038/ cddis.2012.1
-
(2012)
Cell Death Dis
, vol.3
-
-
Kharaziha, P.1
Rodriguez, P.2
Li, Q.3
Rundqvist, H.4
Björklund, A.C.5
Augsten, M.6
Ullén, A.7
Egevad, L.8
Wiklund, P.9
Nilsson, S.10
-
119
-
-
84861040329
-
AEZS-108: atargeted cytotoxic analog of LHRH for the treatmentof cancers positive for LHRH receptors
-
PMID:22577891
-
Engel J, Emons G, Pinski J, Schally AV. AEZS-108: atargeted cytotoxic analog of LHRH for the treatmentof cancers positive for LHRH receptors. Expert OpinInvestig Drugs 2012; 21:891-9; PMID:22577891; http://dx.doi.org/10.1517/13543784.2012.685128
-
(2012)
Expert OpinInvestig Drugs
, vol.21
, pp. 891-899
-
-
Engel, J.1
Emons, G.2
Pinski, J.3
Schally, A.V.4
-
120
-
-
84884915030
-
Trabectedin: A drug from thesea that strikes tumor-associated macrophages
-
PMID:23894721
-
Allavena P, Germano G, Belgiovine C, D'IncalciM, Mantovani A. Trabectedin: A drug from thesea that strikes tumor-associated macrophages. Oncoimmunology 2013; 2:e24614; PMID:23894721; http://dx.doi.org/10.4161/onci.24614
-
(2013)
Oncoimmunology
, vol.2
-
-
Allavena, P.1
Germano, G.2
Belgiovine, C.3
D'Incalci, M.4
Mantovani, A.5
-
121
-
-
84873597334
-
Role of macrophage targeting inthe antitumor activity of trabectedin
-
PMID:23410977
-
Germano G, Frapolli R, Belgiovine C, Anselmo A, Pesce S, Liguori M, Erba E, Uboldi S, Zucchetti M, Pasqualini F, et al. Role of macrophage targeting inthe antitumor activity of trabectedin. Cancer Cell 2013; 23:249-62; PMID:23410977; http://dx.doi. org/10.1016/j.ccr.2013.01.008
-
(2013)
Cancer Cell
, vol.23
, pp. 249-262
-
-
Germano, G.1
Frapolli, R.2
Belgiovine, C.3
Anselmo, A.4
Pesce, S.5
Liguori, M.6
Erba, E.7
Uboldi, S.8
Zucchetti, M.9
Pasqualini, F.10
-
122
-
-
84886944739
-
Immune effects of 5-fluorouracil: Ambivalencematters
-
PMID:23802066
-
Ghiringhelli F, Bruchard M, Apetoh L. Immune effects of 5-fluorouracil: Ambivalencematters. Oncoimmunology 2013; 2:e23139; PMID:23802066; http://dx.doi.org/10.4161/ onci.23139
-
(2013)
Oncoimmunology
, vol.2
-
-
Ghiringhelli, F.1
Bruchard, M.2
Apetoh, L.3
-
123
-
-
84892409579
-
Trial Watch: Lenalidomide-based immunochemotherapy
-
PMID:24482747
-
Semeraro M, Vacchelli E, Eggermont A, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Lenalidomide-based immunochemotherapy. Oncoimmunology 2013; 2:e26494; PMID:24482747; http://dx.doi.org/10.4161/ onci.26494
-
(2013)
Oncoimmunology
, vol.2
-
-
Semeraro, M.1
Vacchelli, E.2
Eggermont, A.3
Galon, J.4
Zitvogel, L.5
Kroemer, G.6
Galluzzi, L.7
-
124
-
-
84885692390
-
Trial watch: Chemotherapy with immunogenic celldeath inducers
-
PMID:23687621
-
Vacchelli E, Senovilla L, Eggermont A, FridmanWH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Chemotherapy with immunogenic celldeath inducers. Oncoimmunology 2013; 2:e23510; PMID:23687621; http://dx.doi.org/10.4161/ onci.23510
-
(2013)
Oncoimmunology
, vol.2
-
-
Vacchelli, E.1
Senovilla, L.2
Eggermont, A.3
Fridman, W.H.4
Galon, J.5
Zitvogel, L.6
Kroemer, G.7
Galluzzi, L.8
-
125
-
-
84878019374
-
Trialwatch: Chemotherapy with immunogenic celldeath inducers
-
PMID:22720239
-
Vacchelli E, Galluzzi L, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Kroemer G. Trialwatch: Chemotherapy with immunogenic celldeath inducers. Oncoimmunology 2012; 1:179-88; PMID:22720239; http://dx.doi.org/10.4161/ onci.1.2.19026
-
(2012)
Oncoimmunology
, vol.1
, pp. 179-188
-
-
Vacchelli, E.1
Galluzzi, L.2
Fridman, W.H.3
Galon, J.4
Sautès-Fridman, C.5
Tartour, E.6
Kroemer, G.7
-
126
-
-
79955810347
-
Globalexperience with ixabepilone in breast cancer
-
PMID:21554041
-
Kaklamani VG, Xu BH, Gomez HL. Globalexperience with ixabepilone in breast cancer. Expert Rev Anticancer Ther 2011; 11:683-92; PMID:21554041; http://dx.doi.org/10.1586/ era.11.41
-
(2011)
Expert Rev Anticancer Ther
, vol.11
, pp. 683-692
-
-
Kaklamani, V.G.1
Xu, B.H.2
Gomez, H.L.3
-
127
-
-
78650256256
-
Patupilone in cancer treatment
-
PMID:21142807
-
Bystricky B, Chau I. Patupilone in cancer treatment. Expert Opin Investig Drugs 2011; 20:107-17; PMID:21142807; http://dx.doi.org/10.1517/135437 84.2011.542148
-
(2011)
Expert Opin Investig Drugs
, vol.20
, pp. 107-117
-
-
Bystricky, B.1
Chau, I.2
-
128
-
-
81255203382
-
Induction of immunogenic apoptosis by blockadeof epidermal growth factor receptor activation witha specific antibody
-
PMID:21984704
-
Garrido G, Rabasa A, Sánchez B, López MV, BlancoR, López A, Hernández DR, Pérez R, Fernández LE. Induction of immunogenic apoptosis by blockadeof epidermal growth factor receptor activation witha specific antibody. J Immunol 2011; 187:4954-66; PMID:21984704; http://dx.doi.org/10.4049/ jimmunol.1003477
-
(2011)
J Immunol
, vol.187
, pp. 4954-4966
-
-
Garrido, G.1
Rabasa, A.2
Sánchez, B.3
López, M.V.4
Blanco, R.5
López, A.6
Hernández, D.R.7
Pérez, R.8
Fernández, L.E.9
-
129
-
-
18744390084
-
Cetuximab
-
PMID:15962524
-
Goldberg RM. Cetuximab. Nat Rev Drug Discov 2005; (Suppl): S10-1; PMID:15962524; http:// dx.doi.org/10.1038/nrd1728
-
(2005)
Nat Rev Drug Discov
, Issue.SUPPL.
-
-
Goldberg, R.M.1
-
131
-
-
41349111281
-
Erlotinib exhibits antineoplastic off-targeteffects in AML and MDS: a preclinical study
-
PMID:17925489
-
Boehrer S, Adès L, Braun T, Galluzzi L, Grosjean J, Fabre C, Le Roux G, Gardin C, Martin A, de BottonS, et al. Erlotinib exhibits antineoplastic off-targeteffects in AML and MDS: a preclinical study. Blood 2008; 111:2170-80; PMID:17925489; http://dx.doi. org/10.1182/blood-2007-07-100362
-
(2008)
Blood
, vol.111
, pp. 2170-2180
-
-
Boehrer, S.1
Adès, L.2
Braun, T.3
Galluzzi, L.4
Grosjean, J.5
Fabre, C.6
Le Roux, G.7
Gardin, C.8
Martin, A.9
de Botton, S.10
-
132
-
-
34447136111
-
A novel epidermal growthfactor receptor inhibitor promotes apoptosis in nonsmallcell lung cancer cells resistant to erlotinib
-
PMID:17616683
-
de La Motte Rouge T, Galluzzi L, Olaussen KA, Zermati Y, Tasdemir E, Robert T, Ripoche H, LazarV, Dessen P, Harper F, et al. A novel epidermal growthfactor receptor inhibitor promotes apoptosis in nonsmallcell lung cancer cells resistant to erlotinib. Cancer Res 2007; 67:6253-62; PMID:17616683; http://dx.doi.org/10.1158/0008-5472.CAN-07-0538
-
(2007)
Cancer Res
, vol.67
, pp. 6253-6262
-
-
de La Motte Rouge, T.1
Galluzzi, L.2
Olaussen, K.A.3
Zermati, Y.4
Tasdemir, E.5
Robert, T.6
Ripoche, H.7
Lazar, V.8
Dessen, P.9
Harper, F.10
-
133
-
-
84886944764
-
Following up tumor-specific regulatory T cells incancer patients
-
PMID:24073383
-
Zitvogel L, Tanchot C, Granier C, Tartour E. Following up tumor-specific regulatory T cells incancer patients. Oncoimmunology 2013; 2:e25444; PMID:24073383; http://dx.doi.org/10.4161/ onci.25444
-
(2013)
Oncoimmunology
, vol.2
-
-
Zitvogel, L.1
Tanchot, C.2
Granier, C.3
Tartour, E.4
-
134
-
-
84876990066
-
Immunomonitoring and prognosticrelevance of neutrophils in clinical trials
-
PMID:23403174
-
Donskov F. Immunomonitoring and prognosticrelevance of neutrophils in clinical trials. SeminCancer Biol 2013; 23:200-7; PMID:23403174; http://dx.doi.org/10.1016/j.semcancer.2013.02.001
-
(2013)
SeminCancer Biol
, vol.23
, pp. 200-207
-
-
Donskov, F.1
|